Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer

Feasibility of Targeted Bronchial Washing Fluid for Molecular Testing With Next Generation Sequencing in Patients With Early-stage Non-small Cell Lung Cancer

This is a single center, clinical trial evaluating the relevance of intratumoral washing for detection of generic alteration with Next Generation Sequencing.

This is a prospective, single-arm, open-label study to assess evaluate the relevance of intratumoral washing by ultrathin bronchoscopy (outer diameter; 3mm) for detection of genetic alterations using Next Generation Sequencing in patients suspicious of early-stage lung cancer.

1. Inclusion Criteria:

   • Age ≥ 20 years
   • Obtained written informed consent
   • Subjects suspected of having resectable lung cancer on computed tomography
   • Subjects without contraindication to brochoscopy
   • Subjects planning to undergo surgery for suspected lung cancer and opting for tissue or liquid biopsy for genetic alteration using Next Generation Sequencing

2. Exclusion Criteria:

   • Subjects who withdraw informed consent
   • Subjects who are unable to undergo liquid biopsy (plasma) and tissue biopsy - for genetic alteration with Next Generation Sequencing based on the investigator's judgement
   • Subjects diagnosed with a cancer other than non-small cell lung cancer from the lung tissue lesion
   • Subjects diagnosed with a benign lesion from the lung tissue lesion